I. Semaglutide: A New Kid on the Block for Nonalcoholic Steatohepatitis, but a Long Way to Go for India: Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021 Mar 25;384:1113–1124. https://doi.org/10.1056/NEJMoa2028395. Epub 2020 Nov 13.

Abstract

Authors have conducted a 72-week, double-blind phase 2 trial involving patients with biopsy biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis of stage F1, F2, or F3. Patients were randomly assigned, in a 3:3:3:1:1:1 ratio, to receive once-daily subcutaneous semaglutide at a dose of 0.1, 0.2, or 0.4 mg or corresponding placebo. The primary end point was resolution of NASH with no worsening of fibrosis. The confirmatory secondary end point was an improvement of at least one fibrosis stage with no worsening of NASH.